Close Menu
Invest Insider News
    Facebook X (Twitter) Instagram
    Saturday, November 21
    Facebook X (Twitter) Instagram Pinterest Vimeo
    Invest Insider News
    • Home
    • Bitcoin
    • Commodities
    • Finance
    • Investing
    • Property
    • Stock Market
    • Utilities
    Invest Insider News
    Home»Finance»Should Long Term Glioma Data Require Action From Nuvation Bio (NUVB) Investors?
    Finance

    Should Long Term Glioma Data Require Action From Nuvation Bio (NUVB) Investors?

    November 21, 20265 Mins Read


    • Nuvation Bio reported long term follow up data from the Phase 2 J201 trial of safusidenib in chemotherapy and radiotherapy naïve grade 2 IDH1 mutant glioma, showing a centrally assessed confirmed clinical benefit rate of 81.5%, a 52% confirmed objective response rate and a 36 month progression free survival rate of 79%.

    • The FDA Fast Track designation granted in August 2026, combined with durable responses and a consistent safety profile over roughly 40 months, is described by the company as supporting safusidenib as a potentially meaningful second oncology franchise alongside IBTROZI, contingent on positive results from later phase trials.

    • We will monitor how Nuvation Bio’s investment narrative evolves as long term safusidenib data is reported and as the company seeks to develop a second revenue pillar.

    Scan the oncology pipeline beyond Nuvation Bio, and line up other potential breakouts with 35 healthcare AI stocks that are pushing new frontiers in targeted treatments and clinical data.

    Nuvation Bio Investment Narrative Recap

    To own Nuvation Bio, you need to believe IBTROZI can keep building a durable ROS1 lung cancer revenue base while safusidenib matures into a true second oncology pillar. The recent Phase 2 safusidenib update strengthens that long term pitch but does not change the reality that the key registrational Phase 3 data sit years away.

    In the near term, the most important swing factor is still execution on IBTROZI uptake and ex U.S. rollouts, because safusidenib is unlikely to affect revenue meaningfully until after pivotal readouts. The biggest risk remains timing and competitive pressure around those long multiyear safusidenib trials, which could extend Nuvation Bio’s reliance on IBTROZI cash flows.

    The analyst consensus Narrative on Simply Wall St frames advancement of safusidenib into a multi trial IDH1 mutant glioma program, including two Phase 3 studies and Fast Track designation, as a major potential second franchise. The new long term J201 data plug directly into that storyline by adding more follow up on response durability and safety in untreated Grade 2 glioma.

    For catalysts, investors are likely to focus on how clean J201 looks as a support beam for the ongoing Phase 3 SIGMA study and the G307 and G209 trials in other IDH1 mutant settings. The operational question now is whether Nuvation Bio can keep recruitment on track, maintain a consistent safety profile and reach those late decade readouts without heavy extra capital needs.

    Nuvation Bio’s current analyst narrative points to revenues of US$471.9 million and earnings of US$17.5 million by 2029, based on an assumed 32.8% yearly increase in revenue and an earnings swing of roughly US$153 million from a loss of US$135.9 million today.

    Uncover why Nuvation Bio’s fair value indicates a 228% potential upside to its current price before that discount closes.

    NYSE:NUVB 1-Year Stock Price Chart
    NYSE:NUVB 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the lowest Nuvation Bio forecasts lean hard into financing risk rather than trial success. Those analysts were only pencilling in about US$384.7 million of revenue and US$66.0 million of earnings by 2029 before this safusidenib update. Treat that as one more lens, and use it to test how your own view might shift as new data land.

    Explore 3 other Nuvation Bio fair value estimates, including one that suggests it could be worth just $12.45!

    Reach Your Own Conclusion

    Don’t just follow the ticker. Dig into the data and build a conviction that is truly your own.

    • A great starting point for your Nuvation Bio research is our analysis highlighting 2 key rewards that could impact your investment decision.

    • See our latest analysis for Nuvation Bio. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Nuvation Bio’s overall financial health at a glance.

    Looking For More Investment Ideas Beyond Nuvation Bio?

    Once you have a view on Nuvation Bio, it can help to widen the lens and line up a few other candidates that fit different roles in your portfolio. Use the Simply Wall St Screener to build a shortlist that matches your risk tolerance, income needs and time horizon.

    • For investors hunting for smaller companies with meaningful upside potential and higher risk, scan through 11 elite penny stocks with strong financials that already show stronger balance sheets and fundamentals than many of their peers.

    • If capital preservation sits high on your priority list, focus on 32 resilient stocks with low risk scores that pair more resilient financial profiles with lower overall risk scores.

    • When you want quality businesses that may not yet be widely followed, sift through 18 high quality undiscovered gems that combine solid fundamentals with the potential to move onto more investors’ radars over time.

    This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include NUVB.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleQuinoa price update: Bolivian white and red FCA Europe, November 2026 — CMB News
    Next Article Bitcoin Falls Below $60K For First Time Since July, Saylor’s MSTR Hits 52-Week Low Amid $14B Paper Loss

    Related Posts

    Finance

    Has AI’s honeymoon ended on Wall Street?

    November 21, 2026
    Finance

    People on the Move: Renault Group, Citigroup, Panmure Liberum, HDFC Bank

    November 20, 2026
    Finance

    EXPERT COMMENT: Football’s financial model | News and events

    November 20, 2026
    Leave A Reply Cancel Reply

    Top Posts

    How is the UK Commercial Property Market Performing?

    December 31, 2000

    How much are they in different states across the US?

    December 31, 2000

    A Guide To Becoming A Property Developer

    December 31, 2000
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews
    Bitcoin

    Institutional money is coming for bitcoin, but Adam Back says it moves slower than you think

    April 28, 2026
    Property

    Property of the week: Manor house with links to Thomas Hardy

    August 16, 2025
    Utilities

    California State Teachers Retirement System Sells 1,127 Shares of Chesapeake Utilities Co. (NYSE:CPK)

    August 9, 2024
    What's Hot

    Bajaj Finance to Shriram Finance, Jefferies top NBFC picks with upto 22% upside – Market News

    August 21, 2025

    Bitcoin Fills CME Gap Amid Trump’s $300M BTC Options Strategy

    July 28, 2025

    Tether CEO Ardoino Denies Bitcoin Selloff Amid Gold Accumulation Talk

    September 7, 2025
    Most Popular

    Embedded Finance vs Banking as a Service in 2026: Key Differences Explained

    April 10, 2026

    Peter Schiff rejette le bitcoin en tant que haie d’un dollar, dit que l’or gagnera en période de faiblesse du dollar

    July 2, 2025

    Bitcoin (BTC) Price Hits $100,000 in Canada

    October 29, 2024
    Editor's Picks

    Files cast light on Jeffrey Epstein’s ties to cryptocurrency | Cryptocurrencies

    February 9, 2026

    Dow sinks 1,000 points, S&P 500, Nasdaq tank with Trump’s tariffs, Powell bashing in focus

    April 21, 2025

    Bitcoin extends losses to the $76,000 level, hitting 2-week low

    May 18, 2026
    Facebook X (Twitter) Instagram Pinterest Vimeo
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions
    © 2026 Invest Insider News

    Type above and press Enter to search. Press Esc to cancel.